Gastroenterology

The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.

Gastroparesis during migraine attacks can hinder oral medication absorption. Migraine experts discuss the connection between gastroparesis and migraine.

MASLD and MetALD were linked to a greater risk of incident IBD, with risk increasing as the number of associated cardiometabolic risk factors increased.

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

Dubinsky describes the evolution from anti-TNF therapies to IL-23 antagonists and the significance of mirikizumab’s approval for Crohn’s disease.

In a validated microsimulation model, annual CRC screening with FIT was the most cost-effective strategy among patients with low adherence.

The approval is based on data from the phase 3 VIVID-1 study and marks mirikizumab’s second approval in IBD, the first being ulcerative colitis in 2023.

Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation.

The randomized trial is the first to assess fecal microbiota transplantation for treating diabetic gastroenteropathy, highlighting its safety and efficacy.

The December month in review spotlights top GI pipeline updates, FDA news, a feature, and IBS research from the final month of 2024.

To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.

This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.

Post-hoc analysis findings suggest tenapanor improves both abdominal and bowel symptoms in adult patients with IBS-C.

The sBLA seeks to expand golimumab’s approval for UC to include pediatric patients ≥ 2 years of age and is supported by data from the PURSUIT program.

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.

Elevated blood insulin levels and insulin resistance each contributed to an elevated risk of colorectal cancer, a new study finds.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

Patients with IBS had different dietary patterns than matched general population controls, with poor diet diversity and quality linked to symptom severity.

Study findings highlight systemic and local autonomic imbalance in patients with IBS-C, pointing to the value of autonomic modulation in this population.

This month in review spotlights GI pipeline updates and news from the 2024 NASPGHAN and ACG annual meetings.

Previous ASA guidance recommended holding GLP-1 RAs in the perioperative period, but new 2024 multisociety guidance suggests a risk-based approach.

An overview and landing page for future installments from HCPLive's 8th annual This Year in Medicine Series.

The supplemental Biologics License Application is supported by the phase 3 ASTRO study of guselkumab SC induction therapy in ulcerative colitis.

HCPLive spoke with Kastl at NASPGHAN about the team’s study on the immune response to the COVID-19 vaccination among children with IBD.

At NASPGHAN, HCPLive spoke to Hamant about her team’s study that showed their algorithm was linked to increased VTE Prophylaxis among Pediatric IBD.

Bifidobacterium longum 35624TM reduces IBS symptom severity in children and adolescents, according to a study presented at NASPGHAN 2024.

Maternal SSRI use was linked to a higher risk of constipation in infants, while untreated maternal depression was tied to colic. Margolis discussed these findings at NASPGHAN.

Computer-aided detection during colonoscopies with AI may help increase adenoma detection rates.